Skip to main content

Medication & Treatment

Research

New vitamin supplement study finds they may do more harm than good

A new study aimed to examine the benefits of vitamin and mineral supplements for prevention of heart disease, stroke and premature death (termed “all-cause mortality”). This found the most commonly studied ones had no effect, while some less common ones did have an effect.

In Australia’s most recent nutrition survey, 29% of people reported having taken at least one dietary supplement. This proportion was even higher in the United States at 52%. A new study out today aimed to examine the benefits of vitamin and mineral supplements for prevention of heart disease, stroke and premature death (termed “all-cause mortality”). This found the most commonly studied […]

Read more

News

Australian Government announces new fee for capsule endoscopy

Posted: May 17 2018

The Australian Government is making changes to two Medicare-funded capsule endoscopy services, following recommendations from the Medical Services Advisory Committee (MSAC) after initial review by the Medicare Benefits Schedule (MBS) Review Taskforce. What are the changes? Capsule endoscopy is a procedure used to record images of the gastrointestinal tract to either diagnose or monitor certain […]

Read more

News

Call for better diagnosis during Crohn’s and Colitis awareness month

Posted: May 4 2018

Getting a solid diagnosis was a long time coming for Ann Turnbull, 39, of Grays Point. Born with an abnormal bowel, she had surgery shortly after birth, and was in and out of hospital as a child.  Doctors told her she has an eating disorder at age 17 because she lost a lot of weight. […]

Read more

Personal Story

Zaun Bhana tells of his experience with Infliximab and colitis

Posted: April 17 2018

My name is Zaun Bhana. I am 30 years old, married to my lovely wife Michelle and we have an 18 month old baby boy named Makan. I own an IT business called LEAP Consulting with a business partner that employs four staff and I have just bought my first house. I am also living […]

Read more

Research

Coping with chronic pain in gastroenterology patients

Author: Roman Jovey MD & Paul C Adams MD

In 2007 an article was published by the National Center for Biotechnology Information. The article interviewed the experienced MDs, Roman Jovey and Paul Adams. Roman, has 20 years of experience dealing with patients who have chronic pain. As such he is an authority on chronic pain management. Crohn’s and Colitis Australia would like to thank […]

Read more

Research

Drug delivery strategies for targeted treatment of inflammatory bowel disease

Author: Lautenschläger C ,  Schmidt C ,Lange K , , Stallmach A

A well-known limitation to current treatments for inflammatory bowel disease, drugs can be described as producing limited therapeutic efficacy as well as some occurrences of adverse effects. In 2015, a handful of researchers published a peer review article addressing these concerns. The article focuses in on the delivery methods of drugs giving an overview of […]

Read more

Research

Inflammatory bowel disease: Potential new treatment target identified

Catharine Paddock

The University of Oxford conducted a study on more than 200 patients’ with inflammatory bowel disease as well as two cohorts from phase 3 clinical trials of infliximab and golimumab. Conclusions drawn from this study suggest that a small protein involved in the inflammatory process could represent an effective target for drugs. As current methods […]

Read more

Research

Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trial

Author: A Cholapranee, G. S Hazlewood, G. G. Kaplan, L. Peyrin-Biroulet, A. N. Ananthakrishnan

In 2017 researchers (A. Cholapranee, G. S Hazlewood, G. G. Kaplan, L. Peyrin-Biroulet, A. N. Ananthakrishnan) performed a meta-analysis of randomised controlled trials to check the effectiveness of mucosal healing as an endpoint of immunosuppressives, anti-tumour necrosis factor α (anti-TNF) or anti-integrin monoclonal antibody therapy for moderate-to-severe CD or UC. The study concluded that the […]

Read more